Regeneron Pharmaceuticals price to sales ratio REGN

Market value divided by revenue over the last twelve months, since 2011.

Today, Oct 23, 2026: 5.3×
10-year median: 6.1×
Against its 10-year history: 28th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.8× to 11.0×
Peer median: 7.5×

Regeneron Pharmaceuticals' price to sales ratio is 5.3× as of Oct 23, 2026.

That is below its ten-year median of 6.1×, lower than on 72% of days in the last ten years.

Over that time it ranged from 3.8× in May 2025 to 11.0× in Jun 2017.

The median for 10 biotech stocks of a similar size is 7.5×.

Price to sales ratio over time

median 6.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.3×	4.3×	5.9×
2025	5.8×	3.8×	5.8×
2024	5.7×	5.6×	9.8×
2023	7.3×	5.7×	7.4×
2022	5.7×	3.8×	6.1×
2021	5.0×	4.8×	7.0×
2020	6.3×	4.9×	9.1×
2019	5.4×	4.2×	7.3×
2018	6.2×	5.2×	7.5×
2017	7.3×	7.3×	11.0×
2016	8.2×	7.6×	13.4×
2015	14.8×	14.6×	18.7×
2014	16.0×	12.2×	16.5×
2013	14.4×	11.3×	17.5×
2012	14.9×	12.5×	26.0×
2011	11.0×	9.1×	12.9×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
REGNRegeneron Pharmaceuticals	5.3×
VRTXVertex Pharmaceuticals	10.6×
ONCBeOne Medicines	7.0×
ALNYAlnylam Pharmaceuticals	6.2×
UTHRUnited Therapeutics	8.0×
INCYIncyte	4.0×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
TECHBIO-TECHNE	9.4×
RGENRepligen	12.7×
Peer median	7.5×

Where Regeneron Pharmaceuticals ranks

#26of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.